Raynaud's phenomenon and Systemic sclerosis (scleroderma)

Summary:

Systemic sclerosis (scleroderma) is found among people with Raynaud's phenomenon, especially for people who are female, 60+ old.

The study analyzes which people have Systemic sclerosis (scleroderma) with Raynaud's phenomenon. It is created by eHealthMe based on reports of 27 people who have Raynaud's phenomenon from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Raynaud's phenomenon?

Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas) is found to be associated with 627 drugs and 996 conditions by eHealthMe. Check the latest studies of Raynaud's phenomenon.

What is Systemic sclerosis (scleroderma)?

Systemic sclerosis (scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin) is found to be associated with 493 drugs and 857 conditions by eHealthMe. Check the latest studies of Systemic sclerosis (scleroderma).

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

27 people who have Raynaud'S Phenomenon and Systemic Sclerosis (Scleroderma) are studied.

Would you have Systemic sclerosis (scleroderma) when you have Raynaud's phenomenon?

Gender of people who have Raynaud'S Phenomenon and experienced Systemic Sclerosis (Scleroderma) *:

female: 95.83 %
male: 4.17 %

Age of people who have Raynaud'S Phenomenon and experienced Systemic Sclerosis (Scleroderma) *:

Common co-existing conditions for these people *:

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 7 people, 25.93%
Depression: 5 people, 18.52%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 18.52%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 14.81%
High Blood Cholesterol: 3 people, 11.11%
High Blood Pressure: 3 people, 11.11%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 11.11%
Blood Pressure Abnormal: 3 people, 11.11%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 11.11%
Anaemia (lack of blood): 2 people, 7.41%

Common drugs taken by these people *:

Common symptoms for these people *:

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 22.22%
Fatigue (feeling of tiredness): 4 people, 14.81%
Injection Site Erythema (redness at injection site): 3 people, 11.11%
Swallowing Difficulty: 3 people, 11.11%
Depression: 3 people, 11.11%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 11.11%
Connective Tissue Disorder (any disease that has the connective tissues of the body): 3 people, 11.11%
Oedema Peripheral (superficial swelling): 3 people, 11.11%
Injection Site Pruritus (severe itching at injection site): 3 people, 11.11%
Joint Pain: 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Systemic sclerosis (scleroderma)?

- Check whether Systemic sclerosis (scleroderma) is associated with a drug or a condition

Related studies:

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Systemic sclerosis (scleroderma) and Raynaud's phenomenon, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.